ArticleCNS neuroscience & therapeutics2026
Integrative Drug-Target Causal Analysis, Single-Cell Sequencing and In-Vivo Validation for Dissecting Molecular Mechanisms Underlying Focal Epilepsy.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsTo identify and verify new drug targets for focal epilepsy.
methodsWe combined single-cell expression data from GSE190452, with genetic data from the eQTLGen alliance and utilized expression-associated single nucleotide polymorphism as an instrumental variable in Mendelian randomization analysis to investigate the causal link between gene expression and focal epilepsy risk. Moreover, co-localization analysis was used to evaluate the genetic mediating effect of gene expression. Potential drug interaction mechanisms involving the protein products of key genes were explored using molecular docking technology. The results were verified using an animal model of temporal lobe epilepsy.
resultsThe results of Mendelian randomization analysis found that four genes (CASP1, FST, IL10RA, and SUCNR1) were significantly associated with focal epilepsy risk in the FinnGen and UK Biobank cohorts. However, only SUCNR1 (odds ratio [OR] = 0.462; 95% confidence interval [95% CI]: 0.240-0.890; p = 0.021) and IL10RA (OR = 0.719; 95% CI: 0.547-0.945; p = 0.018) showed consistent negative correlation, indicating that they may have a protective effect (OR < 1). Meanwhile, CASP1 (OR = 1.260; 95% CI: 1.023-1.553; p = 0.030) and FST (OR = 1.377; 95% CI: 1.044-1.816; p = 0.024) were associated with increased risk (OR > 1).
conclusionCASP1, FST, IL10RA, and SUCNR1 are potential druggable genes and promising therapeutic targets for focal epilepsy treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.